Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.
Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T. Tsamis F, et al. Among authors: baroudy b. J Virol. 2003 May;77(9):5201-8. doi: 10.1128/jvi.77.9.5201-5208.2003. J Virol. 2003. PMID: 12692222 Free PMC article.
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP. Kuhmann SE, et al. J Virol. 2004 Mar;78(6):2790-807. doi: 10.1128/jvi.78.6.2790-2807.2004. J Virol. 2004. PMID: 14990699 Free PMC article.
Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore, Proc. Natl. Acad. Sci. USA 99:395-400, 2002). The escape mutant, CC101.19, continued to use CCR5 for entry, but it was at least 20,000-fold more resistant to AD101 than the parental vir …
Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore, Proc. Natl. Acad. Sci. USA 99:395-400, 2002). …
The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.
Billick E, Seibert C, Pugach P, Ketas T, Trkola A, Endres MJ, Murgolo NJ, Coates E, Reyes GR, Baroudy BM, Sakmar TP, Moore JP, Kuhmann SE. Billick E, et al. J Virol. 2004 Apr;78(8):4134-44. doi: 10.1128/jvi.78.8.4134-4144.2004. J Virol. 2004. PMID: 15047829 Free PMC article.
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, Smith SO, Dragic T, Moore JP, Sakmar TP. Seibert C, et al. Among authors: baroudy bm. Virology. 2006 May 25;349(1):41-54. doi: 10.1016/j.virol.2006.01.018. Epub 2006 Feb 21. Virology. 2006. PMID: 16494916 Free article.
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.
Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. Trkola A, et al. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400. doi: 10.1073/pnas.012519099. Proc Natl Acad Sci U S A. 2002. PMID: 11782552 Free PMC article.
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM. Strizki JM, et al. Among authors: baroudy bm. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12718-23. doi: 10.1073/pnas.221375398. Epub 2001 Oct 16. Proc Natl Acad Sci U S A. 2001. PMID: 11606733 Free PMC article.
Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM. Palani A, et al. Among authors: baroudy bm. J Med Chem. 2001 Oct 11;44(21):3339-42. doi: 10.1021/jm015526o. J Med Chem. 2001. PMID: 11585437
72 results